Vaderis Therapeutics
PrivateLast Round
Series B
Aug 11, 2026
Total Funding Raised
$189.1M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Vaderis Therapeutics is a biotechnology company that develops targeted therapies for rare vascular diseases, with a primary focus on hereditary hemorrhagic telangiectasia.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Vaderis Therapeutics Comparables
Compare Vaderis Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Terremoto Biosciences | 86% | |
| Diagonal Therapeutics | 85% | |
| Kaken Pharmaceutical Co. Ltd | 78% |
Vaderis Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Aug 11, 2026 | ||||
| Series A | May 1, 2020 | ||||
| Series A | Apr 1, 2020 |
Key People
Founding team and executive leadership
Vaderis Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| TCG Crossover | Series B |
| Omega Funds | Series B |
| EQT Life Sciences | Series B |
| Perceptive Advisors | Series B |
| Life Sciences at Goldman Sachs Alternatives | Series B |
| Droia Ventures | Series B, Series A |
| Kalehua Capital Management | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 11, 2026
$152M round led by TCG Crossover and Goldman Sachs.
- Apr 18, 2026
Monthly visitors increased 75% MoM.
Vaderis Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Vaderis Therapeutics's valuation, stock price, and market status.
Is Vaderis Therapeutics a public or private company?
Vaderis Therapeutics is a private company.
What is the current stock price of Vaderis Therapeutics?
Vaderis Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Vaderis Therapeutics worth (valuation)?
Valuation information for Vaderis Therapeutics is not publicly available.
Can I buy Vaderis Therapeutics stock?
Vaderis Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Vaderis Therapeutics's last funding round?
Vaderis Therapeutics's most recent funding round was Series A on May 1, 2020.
Who are the main investors in Vaderis Therapeutics?
Key investors in Vaderis Therapeutics include Medicxi.
Will Vaderis Therapeutics IPO soon?
No public IPO plans have been announced for Vaderis Therapeutics.
How can I track Vaderis Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Vaderis Therapeutics's secondary market activity and sign up for updates.